HIGD1C: A Potential Drug Target and Biomarker (G613227)

Target Name: HIGD1C

NCBI ID: G613227

HIGD1C

HIGD1C: A Potential Drug Target and Biomarker

HIGD1C (UBIE2), a protein that belongs to the UBIE family of genes, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to investigate, and recent studies have shed light on its role in various biological processes.

HIGD1C is a 21-kDa protein that is expressed in various tissues and cells of the body. It is characterized by a N-terminal transmembrane domain, a unique feature that is found in proteins that are involved in cell signaling. This domain is involved in the interaction between HIGD1C and its downstream targets, which are located in the cytoplasm. HIGD1C also has a C-terminal T-loop region and a unique N-end that is rich in conserved amino acid sequence.

One of the most significant features of HIGD1C is its ability to interact with various proteins, including casein kinase (CK) 3. This interaction between HIGD1C and CK3 has been shown to play a role in the regulation of cellular processes such as cell signaling, DNA replication, and apoptosis.

In addition to its interaction with CK3, HIGD1C has also been shown to interact with several other proteins, including the transcription factor, activator of transcription factor-controlled genes (ATF-CG), and the protein kinase B (PKB). These interactions have has been shown to regulate various cellular processes, including cell signaling, cell cycle progression, and protein synthesis.

HIGD1C has also been shown to play a role in the regulation of cellular apoptosis. When HIGD1C is overexpressed, it has been shown to induce apoptosis in various cell types, including cancer cells. This suggests that HIGD1C may be a potential drug target for cancer treatment.

Another potential application of HIGD1C is as a biomarker for various diseases. Its expression has been shown to be regulated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, HIGD1C has been shown to be downregulated in various types of cancer , and its overexpression has been shown to promote the growth and survival of cancer cells. This suggests that HIGD1C may be a potential biomarker for cancer diagnosis and treatment.

In conclusion, HIGD1C is a unique protein that has been identified as a potential drug target and biomarker for various diseases. Its interaction with various proteins and its ability to regulate cellular processes make it an attractive target for research into the mechanisms of these diseases. Further studies are needed to fully understand its role in these processes and its potential as a drug or biomarker.

Protein Name: HIG1 Hypoxia Inducible Domain Family Member 1C

The "HIGD1C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HIGD1C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets